Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Metrics to compare | MIST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMISTPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.9x | 0.8x | −0.5x | |
PEG Ratio | −0.08 | 0.00 | 0.00 | |
Price/Book | −24.7x | 0.5x | 2.6x | |
Price / LTM Sales | - | 1.9x | 3.3x | |
Upside (Analyst Target) | 158.1% | 150.0% | 42.9% | |
Fair Value Upside | Unlock | 5.8% | 6.2% | Unlock |